Guardant Health

Jun 13, 2022

Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture

Jun 1, 2022

360Dx Top 30 Inches Up in May After April Plummet

May 27, 2022

Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit

May 9, 2022

Guardant Health Confident in New CRC Screening Blood Test Despite Competitor Skepticism
Premium

May 5, 2022

Guardant Health Q1 Revenues up 22 Percent

Apr 13, 2022

Guardant Health, Exact Sciences Make Progress on Multi-Cancer Detection Tests
Premium

Apr 4, 2022

Guardant Health Inks Partnership with Epic for EHR Integration of Cancer Tests

Mar 17, 2022

Illumina Sues Guardant Health Over Patents, Trade Secrets, Breach of Contract

Mar 14, 2022

Guardant Health Gets Japanese Approval for Tumor Mutation Profiling Liquid Biopsy Test

Mar 8, 2022

Guardant Health Receives Medicare Coverage for Tissue-Based Cancer Test

Feb 25, 2022

As CRC Screening Launch Approaches, Guardant Health Plans New Comprehensive Assay
Premium

Feb 23, 2022

Guardant Health Q4 Revenues up 38 Percent

Jan 20, 2022

In Ongoing False Advertising Suit, Judge Allows Natera Counterclaims Against Guardant Health

Jan 11, 2022

JP Morgan Healthcare Conference Day 1: Qiagen, Adaptive Bio, Guardant Health, Natera, Sema4

Nov 24, 2021

HER2 Treatments See New Milestones in Colorectal Cancer, With Liquid Biopsy Identifying Responders
Premium

Nov 5, 2021

In Brief This Week: Guardant Health, Scipher Medicine, Centogene, Thermo Fisher, Biofortuna

Nov 4, 2021

Guardant Health Q3 Revenues Up 27 Percent

Sep 1, 2021

360Dx Index Maintains Steady Ascent, Increasing 3 Percent in August

Aug 6, 2021

Guardant Health Laying Path for Future in Cancer Screening, Updates Launch Plans for CRC Assay
Premium

Aug 5, 2021

Guardant Health Q2 Revenues Grow 39 Percent